We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
-2.44%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$732M
AUM Growth
-$47M
Cap. Flow
+$57.5M
Cap. Flow %
7.86%
Top 10 Hldgs %
70.9%
Holding
29
New
3
Increased
6
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
LIAN
LianBio American Depositary Shares
LIAN
+$61.4M
2
VRDN icon
Viridian Therapeutics
VRDN
+$34.2M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$20M
4
RLMD icon
Relmada Therapeutics
RLMD
+$19.6M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$18.3M

Top Sells

Rank Stock Value
1
ALT icon
Altimmune
ALT
+$43M
2
CGEM icon
Cullinan Oncology
CGEM
+$15.9M
3
OLMA icon
Olema Pharmaceuticals
OLMA
+$14.9M
4
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$14.8M
5
CRVS icon
Corvus Pharmaceuticals
CRVS
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 95.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TIL icon
1
Instil Bio
TIL
$48.3M
$117M 16.06%
343,254
– –
ACRS icon
2
Aclaris Therapeutics
ACRS
$726M
$66.4M 9.07%
4,563,962
– –
TVTX icon
3
Travere Therapeutics
TVTX
$5.2B
$61.9M 8.47%
1,994,997
+262,587
+15% +$7.4M
RLMD icon
4
Relmada Therapeutics
RLMD
$557M
$51.1M 6.99%
2,270,072
+882,352
+64% +$19.6M
GHRS icon
5
GH Research
GHRS
$1.93B
$47.2M 6.45%
2,021,985
+379,689
+23% +$8.34M
WHWK
6
Whitehawk Therapeutics
WHWK
$190M
$36.9M 5.05%
1,529,402
– –
VRDN icon
7
Viridian Therapeutics
VRDN
$2.09B
$36.6M 5.01%
1,852,919
+1,833,424
+9,405% +$34.2M
MRNS
8
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$34.2M 4.68%
2,880,096
+238,287
+9% +$2.75M
CLDX icon
9
Celldex Therapeutics
CLDX
$2.99B
$33.4M 4.57%
865,116
-233,058
-21% -$10.2M
TCDA
10
DELISTED
Tricida, Inc. Common Stock
TCDA
$33.4M 4.57%
3,494,851
+3,104,144
+794% +$20M
LIAN
11
DELISTED
LianBio American Depositary Shares
LIAN
$33.1M 4.53%
+5,378,341
New +$61.4M
VTGN icon
12
VistaGen Therapeutics
VTGN
$9.89M
$31.3M 4.28%
534,910
– –
KDNY
13
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$20.9M 2.86%
+1,283,821
New +$18.3M
LENZ
14
LENZ Therapeutics
LENZ
$166M
$20M 2.74%
230,374
– –
NUVL
15
DELISTED
Nuvalent
NUVL
$15.3M 2.09%
803,951
– –
KNTE
16
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$13.7M 1.87%
773,014
-700,000
-48% -$14.8M
LONA
17
LeonaBio Inc
LONA
$66.3M
$13M 1.78%
100,000
-19,620
-16% -$2.48M
CNTA
18
DELISTED
Centessa Pharmaceuticals
CNTA
$12.7M 1.74%
1,127,272
– –
ATYR
19
aTyr Pharma
ATYR
$47.6M
$11.7M 1.6%
1,565,000
– –
COGT icon
20
Cogent Biosciences
COGT
$6.65B
$9.34M 1.28%
1,088,817
– –
AFMD
21
DELISTED
Affimed
AFMD
$7.89M 1.08%
+142,857
New +$8.83M
OLMA icon
22
Olema Pharmaceuticals
OLMA
$1B
$7.64M 1.04%
816,651
-719,542
-47% -$14.9M
CVRX icon
23
CVRx
CVRX
$137M
$6.52M 0.89%
533,370
– –
AKYA
24
DELISTED
Akoya BioSciences
AKYA
$6.12M 0.84%
400,000
– –
ATXS
25
DELISTED
Astria Therapeutics
ATXS
$2.9M 0.4%
538,999
– –
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q4 2021 Portfolio in Review

As of Q4 2021, VR Adviser held 29 positions worth $732M, down 6% from $779M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

VR Adviser deployed $57.5M of net new capital in Q4 2021, opening 3 new positions and adding to 6 existing holdings. Its largest new stake was LianBio American Depositary Shares: 5,378,341 shares worth $33.1M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier.

On the sell side, the largest reduction was Olema Pharmaceuticals, an estimated $14.9M trimmed.

  • VR Adviser's largest Q4 2021 buy was LianBio American Depositary Shares: 5,378,341 shares worth $33.1M.
  • VR Adviser added most to Viridian Therapeutics in Q4 2021, an estimated $34.2M increase.
  • VR Adviser's biggest Q4 2021 reduction was Olema Pharmaceuticals, cutting an estimated $14.9M.
  • VR Adviser fully exited Altimmune in Q4 2021, selling an estimated $43M.
  • VR Adviser's ten largest holdings make up 71% of its $732M portfolio in Q4 2021.
  • VR Adviser opened 3 new positions and closed 3 in Q4 2021.
  • VR Adviser's portfolio value fell 6% quarter-over-quarter to $732M.

Based on VR Adviser's 13F filing for Q4 2021, filed 14 Feb 2022.